How the Rich Invest: John Kahlbetzer

John Kahlbetzer has made his money in agriculture and is now dabbling in small mining stocks.

• Updated May 11, 2016
• John Stensholt

Biotron shares soar on Hepatitis C trial data

Australian drug developer Biotron may have found a potential cure for Hepatitis C, after all patients who completed a trial of its lead antiviral drug emerged with undetectable levels of the virus.

• Updated Oct 10, 2014

• Market Wrap

Biotron (BIT)

Shares in Australian biotechnology company Biotron have surged following the announcement of favourable results in a clinical trial for a treatment it has developed for patients with the hepatitis C virus.

• Updated Oct 19, 2012
• Will Glasgow

• Market Wrap

Biotech stocks guilty by association

This has been a tough period for small-cap investors, but some sectors have taken an added blow due to a dismal update by a major player in that space.

• Updated Jun 1, 2011
• Brendon Lau

A Storm in a petri dish

Experts are doubtful about claims of a breakthrough by a small listed biotech company.

• Jul 31, 2003
• By Beth Quinlivan

Dangerous liaisons

Will getting into bed with business mean universities lose their paramount virtues of independence and integrity? A worldwide reassessment of these uneasy relationships is currently sweeping across Australian campuses

• Feb 22, 2002
• By Ray Moynihan Research assistance from Melanie Corben.

ANU backs Biotron on virus claims

The Australian National University has declared its support for newly listed biotech company Biotron, which is facing further allegations that it may have misled investors

• Jan 30, 2001
• Ray Moynihan

Biotech newcomer faces misleading claims allegations

New biotech company Biotron is facing allegations it has made misleading claims in its prospectus documents, just one day after listing on the Australian Stock Exchange

• Jan 25, 2001
• Ray Moynihan